3Vote!
Medical News Today (Free subscription) | 11/07/2009
Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved ISTODAX® (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. The approval of ISTODAX was based on objective disease response defined as the proportion of patients with confirmed complete response or partial response....
3Vote!
Contract Pharma Breaking News (Free subscription) | 11/06/2009
Gloucester Pharmaceuticals received approval from the FDA for Istodax (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. The approval was based on disease response defined as the number of patients with confirmed complete response or partial response. The NDA included efficacy data from two studies involving 167 patients....
3Vote!
Medical News Today (Free subscription) | 11/06/2009
Cephalon, Inc. (Nasdaq: CEPH) announced the journal Cancer has published a pivotal study demonstrating that TREANDA® (bendamustine HCl) for Injection induced durable responses in patients with indolent B-cell non-Hodgkin's lymphoma (NHL) whose disease had progressed during or within six months of treatment with rituximab.
3Vote!
Medical News Today (Free subscription) | 11/06/2009
A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online in the International Journal of Cancer. The study drug, Bortezomib, was found to be effective against bone cancer in human cancer cell studies and in mice.
3Vote!
Medical News Today (Free subscription) | 11/06/2009
New data published today in the journal, Cancer, reveals that three quarters (75%) of patients with indolent B-cell non-Hodgkin's lymphoma (iNHL), responded to treatment with Bendamustine following a single-arm, multicentre study. Significantly, all patients participating in the study had become resistant or were unresponsive to rituximab (the standard treatment for the disease) when used either as...
6Vote!
Boston Herald (Free subscription) | yesterday
MINNEAPOLIS - A Minnesota teen who fled the state to avoid chemotherapy has finished his cancer treatment. Daniel Hauser of Sleepy Eye underwent his final radiation session...
6Vote!
Star Tribune (Free subscription) | yesterday
Daniel gained national attention when he stopped treatment after one session in February and fled, citing his religious beliefs. After he returned, he underwent court-ordered chemo to treat Hodgkin's lymphoma, then started radiation therapy.
5Vote!
Medical News Today (Free subscription) | yesterday
A rapid decline in metabolic activity on a PET scan after radiation therapy for non-small cell lung cancer is correlated with good local tumor control, according to a study presented by researchers at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting. In addition, the researchers also found that the higher the metabolic activity and tumor size on a PET scan before treatment, the...
3Vote!
Cycling Art Blog (Free subscription) | 11/07/2009
The artisan... Where framebuilding equals art the cycling world can look and marvel at Dario Pegoretti. He was well schooled in the seventies learning framebuilding from none other than the great Luigino Milani. He actually continue building in the Milani shop in Verona until 1999. his art... During the nineties pro teams sought out Pegoretti for his functional frames and badged them under different...
5Vote!
PR News Wire (Free subscription) | 11/06/2009
WHITE PLAINS, N.Y., Nov. 6 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) will again be participating in Gap Inc.'s Give & Get program, which in its first two campaigns this past spring and summer, garnered more than $1 million to support LLS's blood cancer research funding and patient education and support services.
4Vote!
Fiercebiotech (Free subscription) | 11/06/2009
Bethesda, MD-based Micromet has agreed to buy out MedImmune's North American rights to blinatumomab , a potential treatment for lymphoma and leukemia. As a result of the buyout, Micromet now controls global rights to develop and commercialize blinatumomab and any other BiTE antibodies for hematological cancers. The companies inked the blinatumomab agreement in 2003 and planned to create up to six...
3Vote!
Medical News Today (Free subscription) | 11/06/2009
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML).
3Vote!
Medical News Today (Free subscription) | 11/06/2009
Stem Cell Therapy International Inc. (OTCBB: SCII) and its soon to be subsidiary, Histostem Ltd. of South Korea ("Histostem"), announced that they recently supplied hematopoietic stem cells to The Queen Mary Hospital of the University of Hong Kong, China, for treatment of Leukemia patients.
4Vote!
Xconomy (Free subscription) | 11/06/2009
Gloucester Pharmaceuticals has won clearance to start selling its first cancer drug in the U.S. The Cambridge, MA-based biotech company said today it has gotten the green light from the FDA to start marketing its romidepsin treatment, under the brand name Istodax, for patients with a rare malignancy of the skin known as cutaneous T-cell lymphoma. [...]
4Vote!
Business Wire (Free subscription) | 11/05/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved ISTODAX® (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. The approval of ISTODAX was based on objective disease response defined as the proportion of patients with confirmed complete...
5Vote!
xgqaxshmm | 11/02/2009
Tennis Elbow Treatments do not always require a doctor. Learn how to cure tennis elbow without seeing the doctor. http://curesfortenniselbow.com/tennis-elbow-treatment/
6Vote!
andro | 10/30/2009
Reed more about m esothelioma lawsuits, asbestos cancer, mesothelioma cancer here >>> Mesothelioma a rare tumor developing in the pleura, peritoneum or within the pericardium originating from the mesothelium. The development of pleural mesothelioma is very often associated with inhaling asbestos dust a person (see asbestosis), so the workers of enterprises whose... read more ... of mesothelioma cancer...
3Vote!
aarkstore | 10/28/2009
Non-Hodgkin Lymphoma Therapy Area Pipeline Report contains detailed information on the non-hodgkin lymphoma drug pipeline. This report provides insight into the pipeline status of non-hodgkin lymphoma drugs by company and by stage as well as a summary of the latest news and developments in this area. Scope of the report: Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with...
Videos